Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cavilon versus sorbolene for radiation skin reactions after mastectomy
ACTRN12607000100493Phase 3Completed
- Sponsor
- Peter Graham
- Start
- Mar 2004
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Cavilon Durable Barrier Cream and sorbolene in radiodermatitis (2 arms), sponsored by Peter Graham. Primary endpoints: Acute skin toxicity, Clinician score of skin reactions and 2 more. Started Mar 2004; status: completed.
02
Drugs
Cavilon Durable Barrier Creamsorbolene
03
Conditions
radiodermatitis
Beyond the preview
Go deeper on ACTRN12607000100493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000100493.